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STRUCTURED ABSTRACT 
Background. The His-SYNC pilot trial was the first randomized comparison between His bundle 
pacing in lieu of an LV lead for cardiac resynchronization therapy (His-CRT) and biventricular 
pacing (BiV-CRT), but was limited by high rates of crossover. 
Objective. To evaluate the results of the HIS SYNC pilot trial utilizing treatment-received (TR) 
and per-protocol (PP) analyses. 
Methods. The His-SYNC pilot was a multicenter, prospective, single-blinded, randomized, 
controlled trial comparing His-CRT versus BiV-CRT in patients meeting standard indications for 
CRT (e.g., NYHA II-IV patients with QRS>120 ms). Crossovers were required based on 
prespecified criteria. The primary endpoints analyzed included improvement in QRS duration, 
LVEF, and freedom from cardiovascular (CV) hospitalization and mortality.  
Results. Among 41 patients enrolled (64±13 yrs, 38% female, LVEF 28%, QRS 168±18 ms), 21 
were randomized to His-CRT and 20 to BiV-CRT. Crossover occurred in 48% of His-CRT and 
26% of BiV-CRT. The most common reason for crossover from His-CRT was inability to 
correct QRS due to nonspecific intraventricular conduction delay (IVCD=5). Patients treated 
with His-CRT demonstrated greater QRS narrowing compared to BiV (125±22 ms vs. 164±25 
ms [TR], p<0.001;124±19 ms vs. 162±24 ms [PP], p<0.001). A trend towards higher 
echocardiographic response was also observed (80 vs. 57% [TR], p=0.14; 91% vs. 54% [PP], 
p=0.078). No significant differences in CV hospitalization or mortality were observed. 
Conclusions. Patients receiving His-CRT on-treatment demonstrated superior electrical 
resynchronization and a trend toward higher echocardiographic response than BiV-CRT. Larger 
prospective studies may be justifiable with refinements in patient selection and implantation 
techniques to minimize crossovers. 
Word Count: 250 
Keywords: His bundle pacing, biventricular pacing, cardiac resynchronization therapy, heart 
failure 
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INTRODUCTION 
 
 Cardiac resynchronization therapy (CRT) has an established role in the treatment of 
patients with heart failure and electromechanical dyssynchrony with wide QRS duration.1-3  As 
an adjunct to guideline-directed medical therapy, CRT has been consistently shown to improve 
quality of life, NYHA status, and LV remodeling with improvements in ejection fraction and 
reduction in LV dimensions and volumes.4  Mortality reduction was demonstrated in the CARE 
HF trial with CRT pacing alone.2 Despite these benefits, non-response to CRT remains high, 
estimated between 30-40%.5, 6 A possible limitation to conventional CRT is that electrical 
synchronization via biventricular pacing (BiV) is achieved through non-physiological means, via 
fusion of an epicardial LV wavefront with an endocardial wavefront from the right ventricular 
apex.   
 His bundle pacing (HBP) has been to shown to be a viable bailout option for CRT and 
more recently has been evaluated for feasibility as a first-line strategy.7-12  Capture of the native 
conduction system can achieve complete restoration of normal physiologic His Purkinje 
conduction, which may more favorably promote remodeling compared to BiV. Recent data 
suggests that the underlying pathophysiology of left bundle branch block (LBBB) patterns is 
attributable to focal disease located proximally in the left conduction system, which provides a 
mechanistic explanation for QRS correction when proximal pacing circumvents a site of distal 
conduction block with a sufficient pacing stimulus.13  Although there has been growing 
enthusiasm for HBP as a means to electrically correct wide QRS complexes and electrical 
cardiac resynchronization, only a single study reported outcomes comparing BiV-CRT versus 
HBP in lieu of an LV lead for CRT (His-CRT) in a crossover study design.  
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 The His Bundle Pacing versus Coronary Sinus Pacing for Cardiac Resynchronization 
Therapy (His-SYNC) pilot trial was an investigator-initiated, prospective, randomized, 
controlled clinical trial that aimed to assess the feasibility and efficacy of His-CRT as a first-line 
strategy for CRT compared to BiV pacing (BiV-CRT) with regard to both electrocardiographic 
and echocardiographic response. By intention-to-treat analysis, His-CRT did not demonstrate 
improvements in electrocardiographic or echocardiographic parameters as compared to BiV-
CRT.14  Interpretation of these results, however, was confounded by high rates of crossover 
which were mandated by protocol when CRT could not be achieved by the allocated treatment. 
We present secondary on-treatment analysis of His-SYNC to examine the direct effect of 
treatment completed and to describe reasons for crossover. 
 
METHODS 
 The study was conducted at 7 centers and the University of Chicago served as the Study 
Coordinating Site (NCT0270045).  Approval by the local institutional review board (IRB) was 
obtained at each participating center prior to enrollment, and all patients provided written 
informed consent.  Patients were blinded to their treatment-allocation (His-CRT or BiV-CRT) in 
this two parallel-arm study. Enrollment began in May 2016 and ended in June 2018. All data 
were sent to the core laboratory (UChicago) for analysis. An interim analysis was performed 
midway (01/2018) through enrollment to assess for safety, and no significant differences were 
noted.   
Eligible patients with heart failure (HF) greater than 18 years of age meeting American 
Heart Association (AHA)-American College of Cardiology (ACC)-Heart Rhythm Society (HRS) 
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meeting Class 1 or Class II guideline indications for CRT were considered for inclusion.15 
Exclusion criteria included existing CRT device, pregnancy, or inability of the patient to provide 
consent for themselves either due to medical or psychiatric comorbidity.  Subjects were not 
compensated for participation.  
 
Study Procedures 
 The implant procedure was performed as per standard technique for cardiac implantable 
electronic devices. Patients were centrally randomized to assignment to His-CRT or traditional 
coronary sinus lead for biventricular pacing. HBP was performed utilizing the Medtronic 
SelectSecure Model 3830 lead (Medtronic, Minneapolis, MN, USA). Delivery of the lead was 
performed utilizing either the fixed curve Model C315His catheter (Medtronic, Minneapolis, 
MN, USA) or the deflectable Model C304 sheath (Medtronic, Minneapolis, MN, USA), per the 
operator preference. His bundle mapping and lead fixation at the time of implant was performed 
as described previously.10   
Briefly, His bundle mapping was performed using standard fluoroscopic views to assess 
septal orientation in LAO and anterosuperior orientation in RAO. The sheath was positioned 
across the tricuspid annulus and the helix of the lead is introduced beyond the sheath to assess 
local electrograms guided by the atrial-ventricular ratio. The His potential was mapped with 
clockwise rotation of the sheath to direct inferoposteriorly toward the septum and clockwise to 
direct anterosuperiorly away from the septum. Pacing was performed with unipolar and bipolar 
configuration to assess for QRS narrowing at sites with stable His potential recording.  
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Patients allocated to left ventricular (LV) lead for BiV-CRT underwent coronary sinus 
(CS) cannulation and LV lead placement per routine implant procedure.16 LV lead, type, and 
vendor (e.g., Abbott, Biotronik, Boston Scientific, Medtronic, or MicroPort) were left to the 
discretion of the implanting physician. Intraprocedurally, operators were encouraged to target a 
posterolateral or lateral branch of the CS in regions with long electrical delay as assessed by 
surface QRS to LV sense (QLV) timing. Placement of the LV lead into the anterior 
interventricular vein or middle cardiac vein was discouraged.  In order to facilitate optimal lead 
placement, arterial access for levo-phase CS angiography or LV septal mapping to characterize 
site of bundle-branch block was also permitted at the discretion of the implanting physician. 
Crossover was encouraged in patients randomized to BiV when LV lead could not be placed due 
to difficult cannulation of the CS, limited CS branch targets, or phrenic nerve capture resulted in 
diaphragmatic stimulation during BiV. V-V interval timing was adjusted by the implanting 
physician to optimize QRS narrowing. 
Crossover was mandated in patients randomized to His-CRT if the paced QRS width did 
not narrow by at least 20% or to a QRS width of ≤ 130 ms (due to data lack of benefit for BiV at 
QRS widths below this cut-off),17 or if fixation of the HBP lead could not be performed with 
adequate stability or pacing output (≤ 5 V @ 1.0 ms). QRS correction with either nonselective or 
selective capture was accepted, as described in a recent working group recommendations 
statement.18 Corrected QRS width was measured from the onset of the intrinsicoid R-wave noted 
in V1 or V2, as described based on data regarding His engagement from intracardiac left-sided 
recordings.13 An example of patient meeting successful QRS correction is shown in Figure 1.  
 Patients were followed with an incision check at approximately 2 weeks, and routine 
clinical evaluation at 1, 3, 6, and 12 months. Patients underwent device interrogation in-person or 
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remotely at each of the available timepoints. Reported device measurements included lead 
sensing (mV), pacing capture threshold (V), pulse width (ms), and impedance (ohms). In patients 
with multipoint pacing enabled (n=2), measurements utilizing the lowest LV bipole stimulation 
output were utilized for comparison.  
 
Study Endpoints 
The primary endpoints included measures of electrocardiographic (i.e., change in QRS 
width) and echocardiographic (i.e., change in LVEF) parameters at 6 months. Time to first 
cardiovascular (CV) hospitalization or all-cause mortality at 12 months was also examined. 
Patient-level ECG and echocardiographic files were sent to the UChicago core laboratory for 
adjudication and re-assessment.  
QRS widths were measured using electronic calipers (Cardio Calipers, Iconico, 
Philadelphia, PA, USA). Patients with baseline bundle branch block morphology were 
categorized according to the classification set forth in the ACC/AHA/HRS guidelines.19 Patients 
with LBBB pattern that did not meet the Strauss criteria20 (i.e., QRS width ≥130 ms in women, 
≥140 in men, QS or rS in leads V1 and V2, and mid-QRS notching or slurring in 2 of leads V1, 
V2, V5, V6, I, and aVL) were categorized as intraventricular conduction delay (IVCD).  
Echocardiographic assessment was performed by two readers blinded to the type of 
device received. Baseline and follow-up (6-month) transthoracic echocardiography were 
subsequently analyzed offline using the Excelera software platform (Philips Healthcare, 
Andover, MA, USA). Left ventricular end diastolic volume (LVEDV) and left ventricular end 
systolic volumes (LVESV) were calculated using the disk summation method from 
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measurements 4-chamber and 2-chamber views with LVEF calculated using the standard 
formula (i.e., LVEF= [LVEDV-LVESV]/LVEDV).  Echocardiographic response was defined as 
an LVEF improvement by ≥5% from baseline.21  
Secondary outcomes included incidence of CV hospitalization alone and incidence of 
significant ventricular arrhythmia (i.e., ventricular tachycardia [VT] or ventricular fibrillation 
[VF] requiring device therapy) during 12 months of follow-up. Quality of life was also assessed 
utilizing the Kansas City Cardiomyopathy (KCCQ) questionnaire, which was administered at 
baseline, 6, and 12 months, along with assessment of New York Heart Association (NYHA) 
function class. Latest available KCCQ data at 6 or 12 months were used for analysis. Data 
regarding endpoints of interest were collected and stored prospectively a remote database 
(REDCap, Vanderbilt University, Nashville, TN, USA). 
 Procedure-related complications were reported, including those that were implant-related 
(i.e., pneumothorax, perforation, pericardial effusion, implant site hematoma, implant site 
infection) and lead-related (i.e., lead dislodgement, lead fracture, or inability to pace due to high 
threshold or phrenic capture) during follow-up.  
 
Statistical Analysis 
For baseline and clinical characteristics, continuous variables were expressed as means ± 
standard deviations or medians with interquartile ranges and compared with either independent t-
tests, Wilcoxon signed-rank tests, or Mann-Whitney U tests depending upon normality. The 
sample size was estimated based on the primary endpoint of echocardiographic response to test 
the hypothesis that an absolute 10% greater improvement in LVEF would be observed with His-
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CRT compared to BiV, with a significance level (α) = 0.05 and a power of 0.8. Categorical 
variables were expressed as relative counts and percentages and compared with Chi-square tests 
of association or Fisher’s exact tests, as appropriate.  Kaplan‒Meier curves were generated to 
describe time to CV hospitalizations and mortality, and then tested using log-rank tests. All 
statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) 
and STATA MP version 15 (College Station, TX, USA). 
 
RESULTS 
 
Study Population 
A total of 41 patients were enrolled, 21 were initially randomized to His-CRT and 20 to 
BiV, with 1 patient withdrawal prior to device implantation in the BiV arm. The average 
duration of follow-up was 12.2 months, with 1 patient lost to follow-up during the study period. 
Overall, the mean age was 64.6±12.6 years, 38% were female, 63% were Caucasian, 65% 
demonstrated a history of coronary artery disease, 33% had a history of paroxysmal or persistent 
atrial fibrillation (AF), and 48% had a history of chronic kidney disease. Patients were 
maintained on guideline-directed medical therapy with 98% on beta-blockade and 75% on either 
angiotensin-converting enzyme inhibitor (ACE-I), angiotensin II receptor blocker (ARB), or 
combination with neprilysin inhibitor.  
Among the 21 patients that were randomized to His-CRT, 11 patients received successful 
HBP implantation with correction of QRS. Among 20 randomized to BiV, one patient withdrew 
prior to implantation, and 14 patient received successful LV lead implantation.  High rates of 
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crossover were noted in both arms (10/21 [48%] of patients assigned to His-CRT and 5/19 [26%] 
of BiV-CRT), and was not significantly different between the two arms (p=0.20). Analysis 
according to treatment-received (TR) consisted of 16 His-CRT and 24 BiV-CRT patients, and 
per-protocol (PP) analysis included 11 His-CRT and 14 BiV-CRT patients. (Figure 2) No 
significant differences were noted in His-CRT versus BiV-CRT based on baseline demographics 
when analyzed as-treated (Table 1). The mean procedural time 2.9±1.3 hours for His-CRT and 
2.4±1.2 hours for BiV-CRT (p=0.25).  Patients that necessitated crossover had significantly 
longer procedural times than those that were implanted per-protocol (3.3±1.6 vs 2.3±0.9 hours, 
p=.04). 
 
Reasons for Crossovers 
Five patients that crossed over to BiV from His-CRT had IVCD (not meeting Strauss 
criteria) that could not be corrected with narrowing by at least 20% and to a QRS width ≤ 130 
msec. (Figure 3) Three patients demonstrated incomplete QRS narrowing with persistent width 
>130 ms.  In 2 patients, the His bundle could not be mapped. Intraprocedural examples of 
patients demonstrating QRS narrowing and no correction are shown (Supplemental Figure 1).  
Left-septal recordings were available for a subset of patients (n=14), and corrective His bundle 
pacing was most likely in patients with either left intrahisian or block of proximal left bundle 
branch. HBP failed to correct any patient with intact Purkinje activation noted on left septal 
mapping consistent with IVCD. One patient randomized to His-CRT crossed-over to BiV, and 
the CS could not be cannulated; the patient then underwent surgical LV lead placement guided 
by epicardial LV electroanatomic mapping to a region of long delay.  
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In those that crossed over from BiV to His-CRT, suboptimal venous branch targets were 
present (n=2), technical inability to cannulate the coronary sinus or target branch (n=2), and 
vascular occlusion necessitating venoplasty (n=1). Figure 4 shows an example of a patient with 
atretic CS anatomy without favorable targets who underwent successful His-CRT after cross-
over.  
 
Primary Endpoints by On-Treatment Analysis 
 Overall, the average QRS width was 168±18 ms (35 left bundle branch block [LBBB] 
pattern, 2 right bundle branch block [RBBB], and 3 who were chronically right ventricular [RV]-
paced). Among patients with LBBB pattern at baseline, 71% met the Strauss criteria for LBBB. 
Patients undergoing His-CRT according to treatment received demonstrated greater electrical 
resynchronization than patients assigned to BiV-CRT. QRS width narrowed from baseline in 
His-CRT from 174±18 ms to 125±22 ms (p<0.001), versus 165±17 ms to 164±30 ms for BiV-
CRT (p=0.82).  QRS duration was significantly shorter in those that received His-CRT compared 
to those that received BiV-CRT (125±22 ms vs. 164±30 ms;  p<0.001).  
 There were no significant differences in LV volumes or LVEF at baseline in patients 
based on treatment-received. At a median follow-up of 6.2 months, the LVEF improved 
significantly in both arms relative to baseline. Patients receiving His-CRT demonstrated a 
median increase in LVEF from 28.3% (23.0-34.3%) to 34.6% (30.8-45.0%) (p<0.001).  Patients 
that received BiV-CRT demonstrated a median increase in LVEF from 27.7% (23.6-30.7%) to 
32.0% (30.9-40.1%) (p<0.001). Pre and post QRS widths and LVEF are shown by group in 
Figure 5. In analysis by treatment-received, median change in LVEF was numerically higher for 
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His-CRT compared BiV-CRT, but this difference was not statistically significant (+7.2% [5.0-
16.3%] vs. +5.9 [1.5-11.3%], p=0.17). A trend toward higher rates of echocardiographic 
response (80% vs. 57%, p=0.14) was similarly observed.  Decline in LVESV% was similar 
between both groups with a mean -22%±24% for those receiving His-CRT and -19%±14% 
(p=0.62). Electrocardiographic and echocardiographic changes over the study are summarized in 
Figure 6. 
Overall event rates were low during the study period, with a total of 6 CV 
hospitalizations (3 due to HF hospitalization, 2 peri-procedural, and 1 for AF requiring 
cardioversion). Two patients demonstrated VT/VF requiring device therapy in follow-up, one of 
which resulted in pulseless electrical activity and death (BiV-CRT crossed over to His-CRT). 
One other death occurred outside the hospital for which device interrogation data was 
unavailable (His-CRT). There were no significant differences between patients receiving His-
CRT versus BiV with respect to the composite of time to CV hospitalization or all-cause 
mortality. 
 
Primary Endpoints by Per-Protocol Analysis 
When analyzing patients receiving treatment per-protocol allocation, His-CRT was 
superior to BiV for electrical resynchronization (124±19 ms vs. 162±24 ms; p<0.001).  No 
significant difference in median LVEF improvement was observed between groups (median 
increase in LVEF +11.8% His-CRT versus +5.2% BiV, p=0.11) although numerically higher 
response was observed with His-CRT compared to as-treated analysis (Supplemental Figures 2 
and 3).  A stronger trend towards echocardiographic response was found in patients receiving 
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His-CRT in per-protocol comparison (91% versus 54%, p=0.078). Only one patient that 
completed His-CRT per protocol did not demonstrate an improvement in EF.  No difference in 
reduction in LVESV% was seen with -22%±25% improvement with His-CRT versus -19%±17% 
with BiV (p=0.75).  
 
Secondary Endpoints 
 Median NYHA class at baseline was comparable between patients treated with His-CRT 
(median NYHA class 3 [2.25-3.0]) versus BiV-CRT (median NYHA class 2.75 [2.25-3.0]) (p = 
0.66). Improvement by ≥1 functional class was similar between the two groups at 6-months 
(53% His-CRT versus 39% BiV, p=0.41) and at 12 months (25% His-CRT versus 31% BiV, 
p=0.89). No patients declined by ≥1 functional grade at 6 months in either group. At 12 months, 
1 patient declined by a single functional grade in the His-CRT group and none in the BiV group 
(p=1.0). Median total KCCQ score at baseline was 101 points (78-112 points). Rise in KCCQ 
was noted for both patients receiving His-CRT (median +16 points [+8-25 points]) and BiV 
(median +10 points [+2-16 points]), and was not significantly different between the two groups 
(p=0.22).  No differences in VT/VF were observed during follow-up with two events occurring 
in those with His-CRT, and none in patients receiving BiV-CRT (p = 0.16). 
 
Adverse Events 
 A total of four periprocedural complications occurred. One patient with severe peripheral 
vascular disease and prolonged procedure (patient who received BiV-CRT after crossover) 
sustained a transient ischemic attack with aphasia which resolved in follow-up. Two patients 
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developed atrial lead micro-dislodgement associated with pericardial effusion (2 BiV-CRT, one 
of whom had crossed-over). One hematoma in a patient receiving His-CRT patient required 
evacuation without additional sequelae. No infectious complications were observed.  
 
Device Parameters  
 Device parameters at baseline and follow-up are noted in Table 2 according to the 
treatment received. No significant differences were found in right atrial (RA) or right ventricular 
(RV) lead measurements of sensing, threshold, or impedance. QLV was reported in 20 of 24 
patients receiving BiV across both arms (mean 131±29 ms; mean QLV ratio 0.80±0.19). With 
respect to resynchronization pacing, HBP was associated with higher pacing output to achieve 
QRS correction (2.75 V versus 0.85 V, p=0.002) and pacing pulse width (1 ms versus 0.5 ms, 
p<0.001) at baseline and in follow-up. No significant change was found in His lead output or 
pulse-width at baseline when comparing baseline to 6 (2 V at 1 ms, p=0.63 versus baseline) or 12 
months (2.5 V at 1 ms, p=0.99 versus baseline).  Two patients treated with His-CRT were 
observed to have higher correction thresholds with loss of QRS correction in follow-up.  In both 
cases, the His lead was maintained and the configuration of the pacing vector was changed from 
His-tip to His-ring to His-tip to RV coil configuration, which reduced in correction threshold 
(2.25V @ 1.0 ms and 3.75 @1.0 ms). 22  No dislodgements of His or LV leads were seen during 
the 12-month study period in either group.  
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DISCUSSION 
 The major findings of this secondary analysis of HIS SYNC are: 
1) His-CRT was superior to BiV-CRT for electrical resynchronization, as measured by QRS 
narrowing. 
2) Echocardiographic response was numerically but not statistically higher in patients 
receiving His-CRT versus BiV-CRT. 
3) Inclusion of IVCD accounted for the majority of crossovers in patients allocated to His-
CRT. 
 
The His-SYNC pilot trial represents an investigator-initiated collaboration to 
prospectively assess the feasibility of His-CRT in comparison to BiV-CRT. Prior work has 
demonstrated the utility of His-CRT as bailout strategy for failed attempt at traditional CRT and 
a single prospective investigation utilized Y-adapted His and LV leads to compare outcomes in a 
crossover design.9  To the best of our knowledge, the His-SYNC pilot trial is the first 
randomized trial to compare His pacing in lieu of an LV lead with BiV for CRT in clinical 
practice.  Further, it represents the first study in the field that prospectively compares two 
modalities to achieve CRT, but intention-to-treat analysis was confounded by a high rate of 
crossover.  To examine the physiologic effects of His-CRT, we performed secondary analysis 
based on on-treatment principles. Per-protocol analysis provides an assessment of the efficacy of 
His-CRT in an optimal setting. 
Importantly, His-SYNC compared echocardiographic response between two methods to 
achieve CRT rather than medical therapy. In contrast to the intention-to-treat analysis, in which 
patients assigned to His-CRT demonstrated lower baseline EF at baseline, the present analyses 
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showed well-matched groups, with no differences in LV volumes, LVEF, or baseline 
demographics by treatment-received. COMPANION and CARE-HF were the initial landmark 
trials to demonstrate mortality benefit in patients undergoing CRT with BiV compared to 
medical therapy.1, 2 Improvements in LVEF has been inconsistently correlated with the 
magnitude of QRS narrowing23, although when dichotomized, increases in paced QRS duration24 
and duration over 200 ms25 may predict poor response to BiV-CRT.  While there was no 
significant improvement in QRS duration in patients randomized to BiV-CRT in this pilot study, 
LVEF improvements were observed and long mean QLV timing reflect optimized LV lead 
positions. Importantly, reductions in mortality and LV volume indices have been demonstrated in 
pivotal trials with relatively modest EF improvements. In CARE-HF, differences in mean EF 
between patients that received CRT compared with medical therapy were 3.7% at 3 months and 
6.9% at 18 months. Similarly, differences in mean LVEF in MADIT CRT at 1 year between 
patients treated with ICD only versus ICD with CRT were 8% (3% vs 11%).3   
The echocardiographic response for patients receiving His-CRT (median +7.2 [TR] and 
median +11.8 [PP]) is consistent with positive response with His-CRT, but did not reach the 
estimated 10% difference between groups. (Supplemental Figure 4) In the present study, 
differences in medians of approximately 7% were observed in the per-protocol analysis in favor 
of His-CRT over BiV-CRT (p=0.078).  Indeed, when examining response by initial ECG pattern, 
all but one patient who received His-CRT with LBBB pattern fulfilling Strauss criteria at 
baseline demonstrated echocardiographic response. These findings, however, should only be 
interpreted as hypothesis-generating due to the as-treated comparison. When combined with 
previous data, these observations justify the need for larger prospective studies designed to test 
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noninferiority and superiority of this novel technique for cardiac resynchronization. The present 
work also helps to inform the power and sample size calculations for future studies. 
 Pre-specified criteria in the study protocol mandated crossover, and rates were 
particularly high in patients originally randomized to His-CRT. In this regard, this pilot study 
should be interpreted as a comparison between two strategies. The main reason for crossover 
from BiV to His-CRT, which was higher than prior studies (26%), were primarily due to 
unfavorable cardiac venous anatomy. One contributing factor was that LV leads were not placed 
in anterior interventricular or middle cardiac veins, as these locations have been associated with 
modest responses to CRT. In addition, operators were conscious of maximizing electrical delay 
of implanted leads, as QLV was >95 ms in 85% of patients receiving BiV (mean QLV 131±29 
ms; mean QLV/QRS duration ratio 0.80±0.19).  
Analysis of the baseline ECGs in patients that required crossover to BiV from His-CRT 
revealed that 50% of patients exhibited nonspecific IVCD.  The inclusion criteria for this pilot 
trial was a broad population based on current guidelines for traditional BiV-CRT. Subsequent to 
the design of His-SYNC, we have recently demonstrated that IVCD patients with intact Purkinje 
activation based on intracardiac mapping exhibit 0% predictive value for corrective His bundle 
pacing.13   
 
Limitations 
This pilot study with small sample size was underpowered to detect differences less than 
10% between groups and the possibility of a type II error cannot be excluded. The criteria for 
LBBB definitions have been shown to clearly impact the outcomes of CRT studies and 
electrophysiologic definitions are essential to stratify patients that are most likely to benefit from 
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resychronization.26  Implantations tools have not evolved substantially since 2010 with 
introduction of the C315His sheath. Longer helices, deflectable sheaths with septal orientation, 
and variable curves to accommodate variable patient anatomy are likely to improve His 
correction rates and stability of thresholds.  
 
Future Directions 
The present results from this pilot study strongly suggest that His-CRT is not suitable for 
an unselected CRT population. With crossover rates approaching 50% from His-CRT, further 
investigation with the same study protocol is not warranted. The findings of this pilot study 
inform the methodology of the planned HIS SYNC II trial, where refinement in patient selection 
to exclude those with IVCD may reduce crossovers substantially. Future studies that evaluate 
His-CRT should target patients with a LBBB pattern that reflects complete conduction block that 
can be circumvented by His bundle pacing,27 and identify surface ECG characteristics that can 
consistently identify these patients. These mechanistic insights were discovered during the same 
time period in which the present trial was conducted. Additionally, advances in sheath and lead 
technology are necessary to improve implantation success as current delivery tools do not 
adequately address patient variability in heart orientation and chamber dimensions. In addition, 
new approaches are being developed to engage the conduction system, including a novel 
intraseptal fixation technique which captures the left bundle branch and may improve the ability 
to correct distal block in the left bundle with lower thresholds.28 This technique expands options 
available for physiologic pacing in patients whom corrective His bundle pacing is not achievable, 
but will require further prospective evaluation and validation.  
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CONCLUSIONS 
 
In this first randomized pilot trial of His-CRT versus BiV for CRT in clinical practice, 
His-CRT demonstrated superior electrical resynchronization than BiV-CRT in on-treatment 
analysis, with a trend towards greater echocardiographic improvement which did not reach 
significance. These secondary analyses should be interpreted as hypothesis-generating, and 
larger prospective studies with refinements in patient selection and implantation techniques may 
be justifiable to test for differential clinical outcomes between CRT modalities. 
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FIGURE LEGENDS 
 
 
Figure 1: Typical LBBB pattern (QRS width 195ms, top) with successful QRS correction 
(bottom) from nonselective His capture resulting in QRS narrowing to 125 ms measured utilizing 
the onset of the intrinsicoid R-wave in V2.   
 
Figure 2: Flow chart of patients in study. 
 
Figure 3: Examples of 3 patients with IVCD that necessitated crossed over from His bundle 
pacing to biventricular pacing due to inability to correct QRS.  All patients had QRS >130ms but 
did not meet Strauss criteria for LBBB.  A)  66 yo male with NICM, EF 34%, QRS 157 ms that 
improved to 41% with biventricular pacing at 6 months. B) 52 yo female with NICM, EF 20%, 
QRS 177 ms that improved to 30% with biventricular pacing at 5 months.  C) 77 yo male with 
ICM EF 28% QRS 161 with mild improvement to 31% at 8 months with biventricular pacing. 
 
Figure 4: Example of a patient randomized to biventricular pacing that crossed over to His 
bundle pacing. A) Unfavorable anatomy is demonstrated by coronary sinus venography with 
atretic coronary sinus and unfavorable lateral vein targets.  B) Baseline typical LBBB pattern is 
seen with QRS width of 170ms. C) Postimplant chest radiograph demonstrating 3-lead system 
with ICD in RV septum, His bundle lead, and atrial lead. D) 12-lead ECG postimplant shows 
successful resynchronization with His bundle pacing resulting in a final QRS duration of 120 ms. 
This patient demonstrated an echocardiographic super-response to His CRT from 35% to 53% in 
5 months. 
 
Figure 5: Pre and post QRS widths by individual patient in patients receiving His bundle pacing 
for CRT (His-CRT) versus biventricular pacing (BiV-CRT) shown in the top panel. Change in 
LVEF before and after pacing is shown in lower panel. 
 
Figure 6: Change in QRS duration before and after pacing with BiV-CRT versus His-CRT, rate 
of echocardiographic response, and median change in LVEF before and after therapy. 
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TABLES 
 
 
Table 1.  Demographic, electrocardiographic, and echocardiographic characteristics at 
baseline of patients by assignment group. 
 
Table 2. Device parameters in follow-up in by treatment received (His-CRT or BiV) 
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TABLE 1: Baseline demographic, electrocardiographic, and echocardiographic characteristics of 
patients by treatment received 
 
Characteristic His-CRT 
(n=16) 
BiV-CRT 
(n=24) 
p-value 
Sex 7 (43.8%) 8 (33.3%) 0.51 
Age 63.4 ± 13.3 65.5 ± 12.4 0.61 
Height (cm) 167.3 ± 11.9 171.2 ± 11.6 0.31 
Weight (kg) 84.0 (74.9-88.5) 83.5 (77.6-96.0) 0.81 
BMI 28.8 (26.4-33.2) 29.7 (26.2-31.3) 0.99 
Race 
   
     Caucasian 10 (62.5%) 15 (62.5%) 1 
     African-American 5 (31.2%) 7 (29.2%) 1 
     Hispanic 1 (6.2%) 1 (4.2%) 1 
     Other 0 (0.0%) 1 (4.2%) 1 
Medication Use 
   
BB 15 (93.8%) 24 (100%) 0.40 
ACE-I 4 (25.0%) 7 (29.2%) 1 
ARB 4 (25.0%) 6 (25.0%) 1 
ARB/Neprilysin Inhibitor 4 (25.0%) 5 (20.8%) 1 
Amiodarone 1 (6.3%) 7 (29.2%) 0.11 
Digoxin 0 (0.0%) 6 (25.0%) 0.06 
Spironolactone 7 (43.8%) 7 (29.2%) 0.34 
Comorbidities 
   
HTN 11 (68.8%) 19 (79.2%) 0.48 
CAD 8 (50.0%) 15 (62.5%) 0.43 
History of CABG 2 (12.5%) 5 (20.8%) 0.68 
COPD 4 (25.0%) 6 (25.0%) 1 
DM2 8 (50.0%) 11 (45.8%) 0.80 
CKD 8 (50.0%) 11 (45.8%) 0.80 
ESRD 1 (6.67%) 2 (8.3%) 1 
NYHA Class 3.0 (2.25-3.0) 2.75 (2.25-3.0) 0.66 
Electrocardiographic 
   
PR 183 (166-199) 192 (162-244) 0.32 
QRS  174 ± 18 165 ± 17 0.12 
QTc 485 ± 41 479 ± 44 0.65 
Echocardiographic characteristics 
   
LVEDV 184 (163-241) 215 (171-271) 0.29 
LVESV 130 (110-180) 157 (116-195) 0.34 
LVEF 28.0 (23.0-34.0) 27.7 (23.6-30.7) 0.81 
 
Key: Angiotensin-converting enzyme inhibitor, ACE-I; Angiotensin II receptor blocker, ARB; Beta-blocker, BB; Body mass 
index, BMI; Coronary artery disease (>70% stenosis of any vessel), CAD; Coronary-artery bypass graft, CABG; Chronic kidney 
disease, CKD; Chronic obstructive pulmonary disease, COPD; Diabetes mellitus Type 2, DM2; End-stage renal disease, ESRD; 
Left ventricular end-diastolic volume, LVEDV; Left ventricular end-systolic volume, LVESV; Left ventricular ejection fraction, 
LVEF; New York Heart Association, NYHA; PR interval, PR; QRS duration, QRS; Corrected QT interval, QTc  
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TABLE 2: Device Parameters in Follow-up in by on-treatment group (His-CRT or BiV) 
Parameter His-CRT 
(n=16) 
BiV 
(n=24) 
p-value 
Implant measurements 
RA lead sensing (mV) 2.00 (1.50-3.80) 1.75 (1.25-3.50) 0.457 
RA lead capture threshold (V) 0.75 (0.60-1.25) 0.70 (0.50-1.00) 0.134 
RA lead pulse width (ms) 0.40 (0.40-0.50) 0.50 (0.40-0.50) 0.384 
RA lead impedance (ohms) 475 (399-726) 494 (399-600) 0.641 
RV lead sensing (mV) 10.25 (9.40-14.80) 12.00 (7.30-15.10) 0.910 
RV lead threshold (V) 0.50 (0.50-0.75) 0.50 (0.50-1.00) 0.241 
RV lead pulse width (ms) 0.40 (0.40-0.50) 0.40 (0.40-0.50) 0.746 
RV lead impedance (ohms) 513 (475-608) 492.50 (428-555) 0.334 
HIS or LV threshold (V)* 2.75 (1.25-3.38) 0.85 (0.73-1.31) 0.002 
HIS or LV pulse width (ms) 1.00 (1.00-1.00) 0.50 (0.40-0.65) <0.001 
His or LV impedance (ohms) 433 (340-481) 540 (497-680) 0.001 
6 Month Follow-Up 
RA lead sensing (mV) 3.55 (2.50-4.60) 2.40 (1.95-3.55) 0.111 
RA lead capture threshold (V) 0.75 (0.50-0.80) 0.66 (0.55-0.81) 0.721 
RA lead pulse width (ms) 0.40 (0.40-0.40) 0.40 (0.40-0.40) 0.684 
RA lead impedance (ohms) 485 (456-513) 456 (380-513) 0.345 
RV lead sensing (mV) 13.65 (9.13-16.88) 12.50 (11.30-20.00) 0.275 
RV lead threshold (V) 0.50 (0.50-0.75) 0.75 (0.50-1.00) 0.184 
RV lead pulse width (ms) 0.40 (0.40-0.40) 0.40 (0.40-0.40) 0.647 
RV lead impedance (ohms) 456 (399-551) 428 (380-513) 0.361 
HIS or LV threshold (V)* 2.00 (1.00-3.25) 0.94 (0.75-1.25) 0.004 
HIS or LV pulse width (ms) 1.00 (1.00-1.00) 0.40 (0.40-0.50) <0.001 
His or LV impedance (ohms) 295 (284-390) 615 (456-703) <0.001 
* Threshold for QRS correction is reported for His bundle pacing 
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